Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy
Aggressive pituitary tumors (APTs) are associated with significant morbidity and mortality, and effective treatment options are limited. Immune checkpoint inhibitors (ICIs) have revolutionized clinical cancer care; however, there is little experience with these agents in the management of APTs. Vasc...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-11-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2020.576027/full |
id |
doaj-311244e69a514362a94c61ea3349f3fd |
---|---|
record_format |
Article |
spelling |
doaj-311244e69a514362a94c61ea3349f3fd2020-11-25T04:08:22ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922020-11-011110.3389/fendo.2020.576027576027Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition TherapyLydia S. Lamb0Lydia S. Lamb1Hao-Wen Sim2Hao-Wen Sim3Ann I. McCormack4Ann I. McCormack5Ann I. McCormack6Garvan Institute of Medical Research, Sydney, NSW, AustraliaSt Vincent’s Clinical School, University of New South Wales, Sydney, NSW, AustraliaSt Vincent’s Clinical School, University of New South Wales, Sydney, NSW, AustraliaThe Kinghorn Cancer Centre, Sydney, NSW, AustraliaGarvan Institute of Medical Research, Sydney, NSW, AustraliaSt Vincent’s Clinical School, University of New South Wales, Sydney, NSW, AustraliaDepartment of Endocrinology, St Vincent’s Hospital, Sydney, NSW, AustraliaAggressive pituitary tumors (APTs) are associated with significant morbidity and mortality, and effective treatment options are limited. Immune checkpoint inhibitors (ICIs) have revolutionized clinical cancer care; however, there is little experience with these agents in the management of APTs. Vascular endothelial growth factor (VEGF) targeted therapy has reported success in a small number of APT case reports. Here we describe a case of pituitary carcinoma responding to ICI therapy and subsequently VEGF inhibition. We discuss the possible mechanisms and experience with ICI therapy and VEGF inhibitors in the management of APTs, biomarkers that may predict response, and the potential role of combination therapies including ICIs and temozolomide.https://www.frontiersin.org/articles/10.3389/fendo.2020.576027/fullaggressive pituitary tumorspituitary carcinomaimmunotherapyimmune checkpoint inhibitorvascular endothelial growth factor inhibitorbiomarker |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lydia S. Lamb Lydia S. Lamb Hao-Wen Sim Hao-Wen Sim Ann I. McCormack Ann I. McCormack Ann I. McCormack |
spellingShingle |
Lydia S. Lamb Lydia S. Lamb Hao-Wen Sim Hao-Wen Sim Ann I. McCormack Ann I. McCormack Ann I. McCormack Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy Frontiers in Endocrinology aggressive pituitary tumors pituitary carcinoma immunotherapy immune checkpoint inhibitor vascular endothelial growth factor inhibitor biomarker |
author_facet |
Lydia S. Lamb Lydia S. Lamb Hao-Wen Sim Hao-Wen Sim Ann I. McCormack Ann I. McCormack Ann I. McCormack |
author_sort |
Lydia S. Lamb |
title |
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy |
title_short |
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy |
title_full |
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy |
title_fullStr |
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy |
title_full_unstemmed |
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy |
title_sort |
case report: a case of pituitary carcinoma treated with sequential dual immunotherapy and vascular endothelial growth factor inhibition therapy |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Endocrinology |
issn |
1664-2392 |
publishDate |
2020-11-01 |
description |
Aggressive pituitary tumors (APTs) are associated with significant morbidity and mortality, and effective treatment options are limited. Immune checkpoint inhibitors (ICIs) have revolutionized clinical cancer care; however, there is little experience with these agents in the management of APTs. Vascular endothelial growth factor (VEGF) targeted therapy has reported success in a small number of APT case reports. Here we describe a case of pituitary carcinoma responding to ICI therapy and subsequently VEGF inhibition. We discuss the possible mechanisms and experience with ICI therapy and VEGF inhibitors in the management of APTs, biomarkers that may predict response, and the potential role of combination therapies including ICIs and temozolomide. |
topic |
aggressive pituitary tumors pituitary carcinoma immunotherapy immune checkpoint inhibitor vascular endothelial growth factor inhibitor biomarker |
url |
https://www.frontiersin.org/articles/10.3389/fendo.2020.576027/full |
work_keys_str_mv |
AT lydiaslamb casereportacaseofpituitarycarcinomatreatedwithsequentialdualimmunotherapyandvascularendothelialgrowthfactorinhibitiontherapy AT lydiaslamb casereportacaseofpituitarycarcinomatreatedwithsequentialdualimmunotherapyandvascularendothelialgrowthfactorinhibitiontherapy AT haowensim casereportacaseofpituitarycarcinomatreatedwithsequentialdualimmunotherapyandvascularendothelialgrowthfactorinhibitiontherapy AT haowensim casereportacaseofpituitarycarcinomatreatedwithsequentialdualimmunotherapyandvascularendothelialgrowthfactorinhibitiontherapy AT annimccormack casereportacaseofpituitarycarcinomatreatedwithsequentialdualimmunotherapyandvascularendothelialgrowthfactorinhibitiontherapy AT annimccormack casereportacaseofpituitarycarcinomatreatedwithsequentialdualimmunotherapyandvascularendothelialgrowthfactorinhibitiontherapy AT annimccormack casereportacaseofpituitarycarcinomatreatedwithsequentialdualimmunotherapyandvascularendothelialgrowthfactorinhibitiontherapy |
_version_ |
1724426122349772800 |